)
|
|
|
|
|
PVT6101
|
| Lifescience Market |
|
2 ug |
|
|
|
|
PVT6102
|
| Lifescience Market |
|
2 ug |
|
|
|
|
PVT17083
|
| Lifescience Market |
|
2 ug |
|
|
|
|
PVT1312
|
| Lifescience Market |
|
2 ug |
|
|
|
|
B1114-25
|
| ApexBio |
|
25 mg |
|
Description: T 705(Favipiravir) is a RNA-directed RNA polymerase NS5B inhibitor.
|
|
|
|
|
|
B1114-5
|
| ApexBio |
|
5 mg |
|
Description: T 705(Favipiravir) is a RNA-directed RNA polymerase NS5B inhibitor.
|
|
|
|
|
|
B1114-5.1
|
| ApexBio |
|
10 mM (in 1mL DMSO) |
|
Description: T 705(Favipiravir) is a RNA-directed RNA polymerase NS5B inhibitor.
|
|
 and CRE co-expression stable cell line (puromycin))
|
|
|
SC021-Puro
|
| GenTarget |
|
2 x 106 cell/ml x 1ml |
|
Description: Luciferase (firefly) and CRE recombinase co-expression stable cell line with Puromycin marker.
|
|
)
|
|
